Comparison
Two separate pairs are shown: DXM + A and DXM + B. Assessing DXM + A + B falls outside the scope of this comparison.
In a study of 18 healthy participants, a THC-dominant extract did not inhibit the CYP enzymes studied, whereas a CBD-rich extract inhibited several CYP enzymes but not CYP2D6.
A CBD-dominant product is not necessarily THC-free or free of other metabolic interactions. The negative CYP2D6 finding is specific to the studied formulation and endpoint [10].
In a study of 12 healthy adults, a single low exposure to kratom tea did not change DXM AUC or Cmax when DXM was used as a CYP2D6 probe.
Under the studied conditions, no significant changes in these DXM pharmacokinetic measures were found. The result concerns a single low exposure to kratom tea. Higher or repeated exposures and concentrates are outside that scope. PHI 3–5 rests principally on extrapolation; the probability of sedation or aspiration remains uncertain [29].
Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations.
These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.
Current linezolid labeling also reports no observed serotonin-syndrome signs in the studied DXM combination [39, 40].
Select two separate DXM interaction entries.